Siccardi AG - Search Results

1

Correction: Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting.

Boselli D, Panigada M, Di Terlizzi S, Romanò M, Canonico E, Villa C, Minici C, van Anken E, Soprana E, Siccardi AG. Boselli D, et al. Among authors: siccardi ag. J Transl Med. 2023 Sep 28;21(1):673. doi: 10.1186/s12967-023-04480-1. J Transl Med. 2023. PMID: 37770922 Free PMC article. No abstract available.

2

Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting.

Boselli D, Panigada M, Di Terlizzi S, Romanò M, Canonico E, Villa C, Minici C, van Anken E, Soprana E, Siccardi AG. Boselli D, et al. Among authors: siccardi ag. J Transl Med. 2023 Jul 23;21(1):495. doi: 10.1186/s12967-023-04353-7. J Transl Med. 2023. PMID: 37482614 Free PMC article.

3

The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19.

Armengaud J, Delaunay-Moisan A, Thuret JY, van Anken E, Acosta-Alvear D, Aragón T, Arias C, Blondel M, Braakman I, Collet JF, Courcol R, Danchin A, Deleuze JF, Lavigne JP, Lucas S, Michiels T, Moore ERB, Nixon-Abell J, Rossello-Mora R, Shi ZL, Siccardi AG, Sitia R, Tillett D, Timmis KN, Toledano MB, van der Sluijs P, Vicenzi E. Armengaud J, et al. Among authors: siccardi ag. Environ Microbiol. 2020 Jun;22(6):1997-2000. doi: 10.1111/1462-2920.15039. Environ Microbiol. 2020. PMID: 32342578 Free PMC article.

4

Strategies to obtain multiple recombinant modified vaccinia Ankara vectors. Applications to influenza vaccines.

Barbieri A, Panigada M, Soprana E, Di Mario G, Gubinelli F, Bernasconi V, Recagni M, Donatelli I, Castrucci MR, Siccardi AG. Barbieri A, et al. Among authors: siccardi ag. J Virol Methods. 2018 Jan;251:7-14. doi: 10.1016/j.jviromet.2017.10.003. Epub 2017 Oct 4. J Virol Methods. 2018. PMID: 28987424

5

AllergoOncology - the impact of allergy in oncology: EAACI position paper.

Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, Dombrowicz D, Daniels-Wells TR, Fazekas J, Fiebiger E, Gatault S, Gould HJ, Janda J, Josephs DH, Karagiannis P, Levi-Schaffer F, Meshcheryakova A, Mechtcheriakova D, Mekori Y, Mungenast F, Nigro EA, Penichet ML, Redegeld F, Saul L, Singer J, Spicer JF, Siccardi AG, Spillner E, Turner MC, Untersmayr E, Vangelista L, Karagiannis SN. Jensen-Jarolim E, et al. Among authors: siccardi ag. Allergy. 2017 Jun;72(6):866-887. doi: 10.1111/all.13119. Epub 2017 Jan 23. Allergy. 2017. PMID: 28032353 Free PMC article. Review.

6

Cutting Edge: IgE Plays an Active Role in Tumor Immunosurveillance in Mice.

Nigro EA, Brini AT, Yenagi VA, Ferreira LM, Achatz-Straussberger G, Ambrosi A, Sanvito F, Soprana E, van Anken E, Achatz G, Siccardi AG, Vangelista L. Nigro EA, et al. Among authors: siccardi ag. J Immunol. 2016 Oct 1;197(7):2583-8. doi: 10.4049/jimmunol.1601026. Epub 2016 Aug 26. J Immunol. 2016. PMID: 27566822

7

A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes.

Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, Mishin V, Di Pietro A, Vicenzi E, Siccardi AG, Clementi M, Burioni R. Clementi N, et al. Among authors: siccardi ag. PLoS One. 2011;6(12):e28001. doi: 10.1371/journal.pone.0028001. Epub 2011 Dec 5. PLoS One. 2011. PMID: 22162996 Free PMC article.

8

An antitumor cellular vaccine based on a mini-membrane IgE.

Nigro EA, Soprana E, Brini AT, Ambrosi A, Yenagi VA, Dombrowicz D, Siccardi AG, Vangelista L. Nigro EA, et al. Among authors: siccardi ag. J Immunol. 2012 Jan 1;188(1):103-10. doi: 10.4049/jimmunol.1101842. Epub 2011 Nov 28. J Immunol. 2012. PMID: 22124126

9

Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene.

Soprana E, Panigada M, Knauf M, Radaelli A, Vigevani L, Palini A, Villa C, Malnati M, Cassina G, Kurth R, Norley S, Siccardi AG. Soprana E, et al. Among authors: siccardi ag. J Virol Methods. 2011 Jun;174(1-2):22-8. doi: 10.1016/j.jviromet.2011.03.013. Epub 2011 Mar 16. J Virol Methods. 2011. PMID: 21419167

10

The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.

Di Lullo G, Soprana E, Panigada M, Palini A, Agresti A, Comunian C, Milani A, Capua I, Erfle V, Siccardi AG. Di Lullo G, et al. Among authors: siccardi ag. J Virol Methods. 2010 Feb;163(2):195-204. doi: 10.1016/j.jviromet.2009.09.016. Epub 2009 Sep 22. J Virol Methods. 2010. PMID: 19778556

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page